Can you take tofacitinib while breastfeeding?

What LactMed would consider instead

LactMed ends this record by naming the drugs it would consider in place of tofacitinib. Whether any of them fits depends on what you are treating — this is the database’s list, not a recommendation from us.

• Adalimumab
• Certolizumab Pegol
• Etanercept
• Infliximab
• Tocilizumab

How much tofacitinib gets into breastmilk

Maternal Levels. A woman with treatment-refractory ulcerative proctitis was started on tofacitinib 10 mg twice daily. She was nursing her 30-month-old daughter once daily. She stopped breastfeeding when tofacitinib was started, but collected 37 timed milk samples over 14 hours after a dose 25 days after stopping breastfeeding while she was still producing milk. The highest tofacitinib milk concentration of 54.5 mcg/L occurred 4 hours after the dose and the lowest milk concentration of 2 mcg/L occurred 14 hours after the dose. Based on the highest milk concentration, the infant would receive 3.4% of the mother’s weight-adjusted dosage.

One nursing mother taking tofacitinib 5 mg twice daily donated 18 prenursing milk samples on days 20 to 22 postpartum. The median level was 7.8 mcg/L (range 1.8 to 32.8 mcg/L). The highest milk concentration of 32.8 mcg/L occurred 3.5 hours after a maternal dose of tofacitinib. The lowest concentration of 1.8 mcg/L occurred 11.3 hours after the previous tofacitinib dose. Based on the highest milk level, the worst-case daily infant dosage was 4.9 mcg/kg, equating to a weight-adjusted relative infant dose of 3.4%.

Infant Levels. Relevant published information was not found as of the revision date.

What has been seen in breastfed infants

Two mothers took tofacitinib during pregnancy while breastfeeding exclusively. One infant whose mother was taking a dose of 10 mg twice daily was breastfed for 6 weeks. At 3.5 of age the infant had normal growth and psychomotor development, and no negative safety signals were seen. The infant received the mandatory non-live vaccinations without complications. A second infant, whose mother was taking tofacitinib 5 mg twice daily and vedolizumab 300 mg every 4 weeks for ulcerative colitis postpartum was followed. She breastfed her infant exclusively for the first 6 months postpartum, and continued breastfeeding for at least 16 months. The child demonstrated normal growth and psychomotor development. The infant received 3 doses of a required hexavalent vaccine (tetanus, diphtheria, polio, pertussis, hepatitis B, and Haemophilus influenza type B) as well as optional non-live vaccines (pneumococcal and meningococcal vaccines) on schedule at 3, 5, and 14 months, with no adverse events reported. At 12 months of age, the child contracted chickenpox, which had a mild course. No other infectious complications were noted. A blood sample was collected from the child at 15 months. Laboratory analysis revealed normal levels of immunoglobulin classes, except for a slightly reduced total IgG antibody level and non-significant anemia. The titers of post-vaccination antibodies were within the typical range for a healthy population, indicating a normal response to vaccination. Extended T-cell and B-cell immunophenotyping was normal, except for mild, non-significant deviations in some T-cell and B-cell populations. The neonatal screening for severe combined immunodeficiency (SCID) was negative. No severe or clinically meaningful pathological findings were observed.

A woman was taking tofacitinib 10 mg twice daily for ulcerative proctocolitis. She reduced the dose to 5 mg twice daily at week 23 of pregnancy and continued it for the rest of her pregnancy and while breastfeeding (extent not stated). At 12 weeks of age, the infant underwent a thorough immunologic evaluation that was normal. The infant was given two doses of the live rotavirus vaccine (Rotarix, GlaxoSmithKline) at weeks 13 and 20 of age. No adverse events were reported following immunization, including severe vomiting, diarrhea or intussusception, with active and passive surveillance. The infant was healthy at 12 months of age.

A woman was given tofacitinib 10 mg twice daily for treatment of alopecia universalis. She had two pregnancies. After her first pregnancy, she exclusively breastfed her infant and resumed tofacitinib 10 mg twice daily at about 4 weeks postpartum without timing of breastfeeding with respect to doses. The infant was followed for 24 months, and no immediate adverse effects were seen. In her second pregnancy, the dose of tofacitinib was reduced to 5 mg twice daily at 4 months of gestation. She exclusively breastfed her infant with no reported immediate adverse effects.

Effects on milk supply

Relevant published information was not found as of the revision date.